Telomir Pharmaceuticals closes acquisition of TELI, secures global rights to Telomir-1
PUBT · 04/24 13:03
Share
Listen to the news
- Telomir Pharmaceuticals closed its acquisition of TELI Pharmaceuticals, securing global rights to Telomir-1 (Telomir-Zn).
- TELI became wholly owned subsidiary, consolidating previously split North American and international rights under one structure.
- Deal used stock-for-stock consideration, with former TELI shareholders receiving Telomir common stock subject to a six-month lock-up.
- Transaction brought USD 1 million in funding at closing.
- Former TELI shareholders may contribute up to USD 4 million tied to IND acceptance and Phase 1/2 trial initiation milestones.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telomir Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202604240900ACCESSWRNAPR_____1160674) on April 24, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved